Anticoagulant-induced oral bleeding

Authors

  • Victor Costa São Paulo State University (Unesp) – Institute of Science and Technology – São José dos Campos – Department of Biosciences and Oral Diagnosis – SP – Brazil.
  • Estela Kaminagakura São Paulo State University (Unesp) – Institute of Science and Technology – São José dos Campos – Department of Biosciences and Oral Diagnosis – SP – Brazil.

DOI:

https://doi.org/10.14295/bds.2017.v20i3.1379

Abstract

Warfarin is an anticoagulant used to prevent thrombosis, cardiac arrhythmias, atrial fibrillation, and recurrence of pulmonary embolism. A 69-year-old male patient reported episodes of four heart attacks, stroke, pulmonary emphysema, varicose veins, thyroid dysfunction, and a history of angioplasty. They use daily dose of 5 mg. Intraoral clinical examination revealed a bleeding nodular lesion of purple color with irregular borders and a smooth surface. The prothrombin time was 68.9 seconds, activity was 10%, and the international normalized ratio (INR) was 8.26. Based on these results, the patient received a single dose of 2.5 mg vitamin K via subcutaneous route. The final diagnosis was oral anticoagulant-induced lesions. Clinicians should be familiar with the side effects of anticoagulants, which are rare in the oral cavity, but can be life-threatening if diagnosed late or inaccurately, especially in older patients that often use many drugs.

Keywords

Anticoagulant; Hemorrhage; Warfarin; Mouth.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2017-09-12

How to Cite

1.
Costa V, Kaminagakura E. Anticoagulant-induced oral bleeding. BDS [Internet]. 2017 Sep. 12 [cited 2025 Aug. 21];20(3):158-60. Available from: https://bds.ict.unesp.br/index.php/cob/article/view/1379

Issue

Vol. 20 No. 3 (2017): Jul. - Sep. / 2017 - Published September 2017

Section

Case Report or Clinical Technique

License

Brazilian Dental Science uses the Creative Commons (CC-BY 4.0) license, thus preserving the integrity of articles in an open access environment. The journal allows the author to retain publishing rights without restrictions.

=================

COPYRIGHT TRANSFER AND RESPONSIBILITY STATEMENT
 (PDF)

For all articles published in the BDS journal, copyright is retained by the authors. Articles are licensed under an open-access Creative Commons CC BY 4.0 license, meaning that anyone may download and read the paper for free. In addition, the article may be reused and quoted, provided that the original published version is cited. These conditions allow for maximum use and exposure of the work while ensuring that the authors receive proper credit. All metadata associated with published articles is released under the Creative Commons CC0 Universal Public Domain Dedication.

Before the submission, authors must obtain permission to reproduce any published material (figures, schemes, tables, or any extract of a text) that does not fall into the public domain or for which they do not hold the copyright. Permission should be requested by the authors from the copyright holder (usually the Publisher, please refer to the imprint of the individual publications to identify the copyright holder).

The authors hereby attest that the study is original and does not present manipulated data, fraud, or plagiarism. All names listed made a significant scientific contribution to the study, are aware of the presented data, and agree with the final version of the manuscript. They assume complete responsibility for the ethical aspects of the study.

This text must be printed and signed by all authors. The scanned version should be submitted as supplemental file during the submission process.

Most read articles by the same author(s)